MAPT and Alzheimer disease: A combination of using plasma tau phosphorylated at threonine 181 (p-tau-181), neurofilament light chain (Nfl), and glial fibrillary acidic protein (GFAP) for the discrimination of AD, frontotemporal dementia, and dementia with Lewy bodies, has been recommended [72].